BRYAN SAUTER: Open Payments
NPI 1407944820 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,443 in 107 payments from 23 companies in 2025. Trend: 2023 $1,331 · 2024 $2,258 · 2025 $3,443
Food & beverage: $2,768Consulting: $675
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $1,079 |
| ABBVIE INC. | 23 | $419 |
| Madrigal Pharmaceuticals | 11 | $406 |
| Janssen Biotech, Inc. | 17 | $405 |
| Phathom Pharmaceuticals, Inc. | 7 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $143 |
| GENZYME CORPORATION | 3 | $121 |
| Boston Scientific Corporation | 1 | $114 |
| Aimmune Therapeutics, Inc. | 1 | $91 |
| Ardelyx, Inc. | 2 | $90 |
Products named: XIFAXAN, REZDIFFRA, TREMFYA, DUPIXENT, VOQUEZNA, RINVOQ, CREON, LINZESS.
Industry payments across CA — which companies pay providers there.
